Video
Jelmyto a “paradigm shift” in treating upper tract urothelial carcinoma
Author(s):
“What's great about [Jelmyto] is you can avoid a pretty morbid operation in a typically unhealthy older population, and treat them with localized therapy,” says Jason M. Hafron, MD.
Video Player is loading.
In a video interview conducted at the 2021 LUGPA annual meeting, Jason M. Hafron, MD, discusses his experience with mitomycin-containing reverse thermal gel (Jelmyto) in the treatment of low-grade upper tract urothelial cancer. Hafron is a partner at the Michigan Institute of Urology, PC; an associate professor of urology at the William Beaumont School of Medicine, Oakland University; and the director of robotic surgery at Beaumont Hospital Royal Oak in Michigan.
Related Videos
5 key trial insights from AUA 2025
Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
Kevin Zorn, MD, on preserving ejaculation with BPH therapies
Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
Alexander Glaser, MD, on real-world outcomes with Aquablation
Vitaly Margulis, MD, on preliminary safety, efficacy of padeliporfin VTP for UTUC
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Margaret Knoedler, MD, on Ho:YAG vs thulium fiber laser for ureteroscopy
John Gore, MD, on radical cystectomy vs bladder-sparing therapy for NMIBC
Related Content
